Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$-0.52
EPS est.
$-0.38
EPS surprise
-36.84%
1-day move
-0.08%
Centessa Pharmaceuticals reported a larger-than-expected loss per share, which may raise concerns among investors about the company's financial health. The stock reacted slightly down by 0.08%, indicating a muted response to the earnings report. Without additional context from management commentary or guidance, investors are left to assess the implications based solely on the reported EPS.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.52 | N/A | -36.84% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.
Centessa Pharmaceuticals plc (CNTA) is a biotechnology company focused on developing innovative therapies for serious diseases. With a market cap of $6 billion, it operates in the health care sector, aiming to address unmet medical needs through its diverse pipeline of drug candidates.
Last quarter
In Q4 2025, Centessa reported an EPS of -$1.46, significantly missing estimates, which led to a 44% increase in stock the following day. This volatility reflects investor sentiment and potential for recovery despite the disappointing earnings.
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
-51.59%
Avg 1-day reaction
+6.48%
Overall expectations for Centessa's upcoming earnings are mixed, with uncertainty surrounding its ability to meet or exceed prior performance. Investors are keenly watching for any signs of improvement in its drug pipeline.
Bull case
If Centessa can demonstrate progress in its clinical trials or provide positive updates on its drug candidates, it could lead to a strong rebound in investor confidence and stock price.
Bear case
Conversely, if the company reports further losses or delays in its pipeline, it may lead to a decline in stock value as investors reassess the company's future prospects.
The print will turn on these.
Q1
What specific advancements can Centessa report regarding its drug candidates?
Updates on drug development are crucial for investor confidence and can significantly impact stock performance.
Q2
Will the company provide any guidance on future revenue expectations?
Guidance on revenue can help investors gauge the company's growth trajectory and market potential.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may be underestimating the potential for Centessa's drug pipeline to yield positive results, despite recent setbacks.
Supporting evidence
The options market is pricing a smaller move than historical averages, suggesting a lack of confidence in a significant downturn.
Centessa's recent stock price movements indicate that investors may be overly pessimistic about its future prospects.
Key risk
If Centessa reports any positive developments in its drug pipeline, it could significantly shift market sentiment.
Pre-commit to what would confirm each case.
The core debate revolves around Centessa's ability to execute on its drug development plans and the financial implications of its current performance.
Bull confirmed if
A positive update on clinical trial results or a new partnership would signal strong potential for growth.
Bear confirmed if
Further delays in the drug pipeline or larger-than-expected losses would confirm bearish sentiment.
What the market is pricing for the move.
Implied Move
±4.03%
Historical Avg
±8.35%
The options market is pricing in a modest move of around 4%, indicating uncertainty about the upcoming earnings report.
Options are pricing a 4.03% move, while the stock has averaged an 8.35% move historically, suggesting a potentially undervalued setup.
ATM IV
0.1%
30d HV
108.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Centessa beats expectations, history suggests a potential average move of +0.49%, confirming a positive outlook for the company.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await more clarity.
Miss
Should the company miss expectations, history suggests an average move of +10.37%, indicating a possible sell-off as investors react to the news.
The lines on the call that would change the story.